Thymosin Alpha-1 Simply Explained

1. What It Is About

Thymosin Alpha-1 is a small protein fragment – experts call such fragments peptides. It consists of 28 building blocks, the amino acids, and was first obtained from the thymus in 1977, an organ in which immune cells mature. For studies it is produced artificially.

The substance belongs to the signalling molecules of the immune system. It does not simply stimulate immunity but intervenes in its regulation: it influences how T-cells (immune cells that recognise infected cells) and dendritic cells (helpers that show other immune cells what to do) mature and function. It is therefore studied where the immune system is out of balance: in severe infections, in blood poisoning (sepsis) and in cancer.

Research has been conducted since the 1970s. The focus remains on infectious diseases and sepsis. Topics such as cognitive performance or metabolism appear only in a few small studies.

2. What Studies Show

Thymosin Alpha-1 is best evidenced in severe blood poisoning (sepsis) and in chronic hepatitis B, a long-lasting liver inflammation caused by the hepatitis B virus.

In blood poisoning: In a large study of 361 patients the participants were randomly assigned to two groups (1). One group received the substance in addition to standard treatment, the other did not. After 28 days, 35 out of 100 patients had died in the group without the substance, compared with 26 out of 100 in the group that received it. The treated patients also showed better values in measures that indicate how well the immune system is functioning. Patients were observed for only 28 days, however.

A summary of several studies on blood poisoning likewise found that mortality decreased; notably, the frequency of administration played a role (5). Other studies tested it together with a second active substance, ulinastatin, and reported better immune values and a better balance of signalling molecules that drive or dampen inflammation (6).

In chronic hepatitis B: In a study of 97 patients who received the substance or a placebo, after twelve months the virus was no longer detectable in the blood of 14 out of 100 treated patients, compared with 4 out of 100 in the control group (2). A larger Japanese study with 316 patients reported that liver values normalised in some of the treated patients and the virus disappeared in about 30 out of 100 (7). Patients with advanced liver scarring responded better to the higher dose.

In metastatic melanoma, a dangerous skin cancer, the group receiving Thymosin Alpha-1 together with dacarbazine responded to treatment more frequently than the group that received dacarbazine alone; however, a survival benefit was not confirmed (3).

The effect on immunity in severe blood poisoning and in chronic hepatitis B is therefore considered well evidenced.

3. What Remains Unclear

The main open question is how much Thymosin Alpha-1 achieves on its own. In most studies patients received additional agents such as interferons or ulinastatin. If the contribution of the individual substance cannot be separated, the results remain ambiguous.

In severe pancreatitis involving 508 patients no clear difference was found in necrotic and infected tissue areas; the informative value was limited because almost all patients were in intensive care (4).

Only a few small studies exist on cognitive performance and metabolism. The question whether Thymosin Alpha-1 changes anything in these areas remains open. Data on long-term effects are also lacking: observation periods extend to 18 months, and whether the virus disappears permanently in hepatitis or mortality declines in the long term is not clarified. In addition, many studies were conducted in Asia, leaving transferability to other populations open.

4. What This Means in Everyday Life

In the studies Thymosin Alpha-1 was not taken orally but injected – and only in people who were already seriously ill: with blood poisoning in intensive care or with chronic hepatitis B. The results therefore relate to such clinical pictures, not to healthy people or everyday life.

Anyone reading the figures should keep two points in mind. First, they refer to groups, not to individuals; within a group some respond and others do not. Second, additional treatment was almost always given, so the contribution of the substance itself is difficult to quantify.

Whether the observed effects are confirmed when the substance is tested alone and over longer periods is the next question to be clarified.

All details with study numbers and sources: detailed page on Thymosin Alpha-1. For children: Thymosin Alpha-1 for Children.